openPR Logo
Press release

Diffuse Large B-cell Lymphoma Therapeutics Market Competitive And Growth Analysis 2024 | Novartis AG, Pfizer Inc., Merck & Co Inc., GlaxoSmithKline plc, F. Hoffmann-La Roche AG, CTI BioPharma Corp.

07-24-2024 09:58 AM CET | Health & Medicine

Press release from: The Business Research Company

Diffuse Large B-cell Lymphoma Therapeutics Global Market Report 2024

Diffuse Large B-cell Lymphoma Therapeutics Global Market Report 2024

"The new report published by The Business Research Company, titled ""Diffuse Large B-cell Lymphoma Therapeutics Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=10805&type=smp

Rising Prevalence Of Diffuse Large B-Cell Lymphoma To Drive Market Growth
The increasing incidence of diffuse large B-cell lymphoma (DLBCL) is expected to propel the growth of the diffuse large B-cell lymphoma therapeutics market going forward. Diffuse large B-cell lymphoma (DLBCL) is a type of aggressive cancer that originates from B-cells in the lymphatic system and is characterized by rapid and diffuse growth. It is a type of non-Hodgkin lymphoma (NHL). The diffuse large B-cell lymphoma therapeutics help to improve outcomes for individuals already diagnosed with the condition by targeting and managing the cancer cells. For instance, the American Cancer Society, a US-based voluntary health organization, estimated that in 2023, about 80,550 people (44,880 males and 35,670 females) will be diagnosed with non-Hodgkin's lymphoma (NHL), where about 20,180 people will die from NHL. Therefore, the increasing incidence of diffuse large B-cell lymphoma (DLBCL) drives the growth of the diffuse large B-cell lymphoma therapeutics market.

Advancements In Drug Therapeutics Transforming The Market
Development drug therapeutics are a key trend gaining popularity in the diffuse large B-cell lymphoma therapeutics market. Major companies operating in the diffuse large B-cell lymphoma therapeutics market are developing drugs for therapies to sustain their position in the market. For instance, in June 2022, Bristol-Myers Squibb, a US-based pharmaceutical company focused on research and development of drugs, received US FDA approval for CAR T Cell Therapy Breyanzi for the treatment of patients with diffuse large B-cell lymphoma (DLBCL), large B-cell lymphoma (LBCL), and relapsed or refractory large B-cell lymphoma. Breyanzi is a CD19-directed chimeric antigen receptor (CAR) T-cell therapy for a broad range of patients having primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and follicular lymphoma grade 3B.

The diffuse large b-cell lymphoma therapeutics market covered in this report is segmented -

1) By Drug Class: Cisplatin, Carboplatin, 5-fluorouracil, Docetaxel, Paclitaxel, Methotrexate, Other Drugs
2) By Therapy: Targeted Therapy, Immunotherapy, Chemotherapy, Other Therapies
3) By Route of Administration: Oral, Parenteral, Other Routes
4) By End User: Hospitals, Clinics, Other End-Users

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=10805&type=discount

Major companies operating in the diffuse large b-cell lymphoma therapeutics market report are Novartis AG, Pfizer Inc., Merck & Co Inc., GlaxoSmithKline plc, F. Hoffmann-La Roche AG, CTI BioPharma Corp., Celltrion Healthcare Co Ltd., Bristol-Myers Squibb Company, AbbVie Inc., Gilead Sciences Inc., Seagen Inc., Kite Pharma Inc., ADC Therapeutics SA, Bayer AG, Erytech Pharma SA, Xencor Inc., Denovo Biopharma LLC, Calithera Biosciences Inc., IMV Inc., Biogen Inc., Autolus Therapeutics plc, Allogene Therapeutics Inc., Spectrum Pharmaceuticals Inc., AstraZeneca PLC, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Aptevo Therapeutics Inc., Takeda Pharmaceutical Company Limited, Johnson & Johnson, Celgene Corporation, Eli Lilly and Company, Sanofi SA, Seattle Genetics Inc., Karyopharm Therapeutics Inc., TG Therapeutics Inc., MorphoSys AG,

Contents of the report:
1. Executive Summary
2. Diffuse Large B-cell Lymphoma Therapeutics Market Report Structure
3. Diffuse Large B-cell Lymphoma Therapeutics Market Trends And Strategies
4. Diffuse Large B-cell Lymphoma Therapeutics Market - Macro Economic Scenario
5. Diffuse Large B-cell Lymphoma Therapeutics Market Size And Growth
…..
27. Diffuse Large B-cell Lymphoma Therapeutics Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/diffuse-large-b-cell-lymphoma-therapeutics-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ "

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Diffuse Large B-cell Lymphoma Therapeutics Market Competitive And Growth Analysis 2024 | Novartis AG, Pfizer Inc., Merck & Co Inc., GlaxoSmithKline plc, F. Hoffmann-La Roche AG, CTI BioPharma Corp. here

News-ID: 3596000 • Views:

More Releases from The Business Research Company

Emerging Trends to Reshape the Corporate Governance Services Market: Advancement In Risk Management Through ESG-Focused Digital Solutions as a Key Influencer
Emerging Trends to Reshape the Corporate Governance Services Market: Advancement …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Corporate Governance Services Market Size Growth Forecast: What to Expect by 2025? In recent years, the market size for corporate governance services has greatly expanded. Current projections show that the market will expand from $4.65 billion in 2024 to $5.08 billion in 2025 with a compound annual growth rate
2025-2034 Communication Satellite Operation Service Market Evolution: Disruptions, Innovations, and Untapped Opportunities
2025-2034 Communication Satellite Operation Service Market Evolution: Disruption …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Communication Satellite Operation Service Market Size Valuation Forecast: What Will the Market Be Worth by 2025? The market for communication satellite operation services has witnessed a swift expansion in recent years. The market value, which is projected to increase from $29.54 billion in 2024 to $32.79 billion in 2025,
Global Cloud Financial Operations Market Projected to Grow at 12.8% CAGR, Reaching $21.74 Billion by 2029
Global Cloud Financial Operations Market Projected to Grow at 12.8% CAGR, Reachi …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Is the Expected CAGR for the Cloud Financial Operations Market Through 2025? The market size for cloud financial operations has experienced swift expansion in the past years. The market, which is projected to increase from $11.85 billion in 2024 to $13.41 billion in 2025, boasts a compound annual
Chemical, Biological, Radiological, Nuclear, And Explosive (CBRNE) Threat Detection Instruments Market: Major Trends Reshaping the Future of the Industry
Chemical, Biological, Radiological, Nuclear, And Explosive (CBRNE) Threat Detect …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Will the Chemical, Biological, Radiological, Nuclear, And Explosive (CBRNE) Threat Detection Instruments Industry Market Size Be by 2025? The size of the market for Chemical, Biological, Radiological, Nuclear, and Explosive (CBRNE) threat detection tools has seen a swift expansion in recent times. The market, valued at $2.46 billion

All 5 Releases


More Releases for Therapeutics

Adrenomyeloneuropathy Market: Epidemiology, Therapies, Companies, DelveInsight | …
Adrenomyeloneuropathy emerging therapies are expected to boost the Adrenomyeloneuropathy Market in the upcoming years. DelveInsight has launched a new report on "Adrenomyeloneuropathy - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Adrenomyeloneuropathy, historical and forecasted epidemiology as well as the Adrenomyeloneuropathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Discover about the Adrenomyeloneuropathy market report @ https://www.delveinsight.com/report-store/adrenomyeloneuropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr Some of the
Pompe Disease Market: Epidemiology, Therapies, Companies, DelveInsight | Genzyme …
Pompe Disease emerging therapies, such as MYOZYME (alglucosidase alfa), LUMIZYME, AAV2/8-LSPhGAA, Avalglucosidase alfa, and others, are expected to boost the Pompe Disease Market in the upcoming years. DelveInsight has launched a new report on "Pompe Disease - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Pompe Disease, historical and forecasted epidemiology as well as the Pompe Disease market trends in the United States, EU5 (Germany, Spain,
Dark Genome Therapeutics Market Deep Research Report with Forecast to 2032 | myN …
The qualitative latest Research report (2025-2032) on the Dark Genome Therapeutics Market by Coherent Market Insights Provides a deep dive into key market trends, drivers, challenges, and the competitive landscape. It analyzes market size, revenue, production, and CAGR using validated methodologies to ensure precision. The report highlights tech innovation, pricing trends, consumer behavior, and investment potential - empowering businesses to make informed, strategic moves. Request a Sample Copy: https://www.coherentmarketresearch.com/samplepages/133611 Focused on growth
Hodgkin's lymphoma Therapeutics Market Size Report 2032 | Affimed Therapeutics, …
DelveInsight's "Hodgkin's Lymphoma Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Hodgkin's Lymphoma, historical and forecasted epidemiology as well as the Hodgkin's Lymphoma market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United kingdom and Japan. Discover Key Insights into the Hodgkin's lymphoma Market with DelveInsight's In-Depth Report @ Hodgkin's lymphoma Market Size- https://www.delveinsight.com/sample-request/hodgkins-lymphoma-hl-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Key Takeaways from the Hodgkin's
CRISPR Therapies Pipeline 2024 | Intellia Therapeutics, CRISPR therapeutics, Rep …
DelveInsight's, "CRISPR Therapies Pipeline Insight 2024" report provides comprehensive insights about 25+ CRISPR Therapies Companies and 30+ pipeline drugs in CRISPR Therapies pipeline landscape. It covers the CRISPR Therapies pipeline drug profiles, including clinical and nonclinical stage products. It also covers the CRISPR Therapies therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive CRISPR Therapies pipeline products in this space. Key Takeaways from
Digital Therapeutics Market, Digital Therapeutics Market Size, Digital Therapeut …
The global digital therapeutics market is expected to reach US$ 8,941.1 Mn by 2025 from US$ 1,993.2 Mn in 2017. The market is estimated to grow with a CAGR of 20.8% during the forecast period from 2018 to 2025. North America is the largest geographic market and it is expected to be the largest revenue generator during the forecast period, whereas the market is expected to witness growth at a significant